Abstract
Overview
Introduction
Patients in a clinical population receive drug and non-drug therapy for female
sexual dysfunction, yet a third remain refractory to treatment highlighting a
need for a formally approved product for FSD. There is a low level of
satisfaction with the classification guidelines, further limiting diagnosis,
already hampered by embarrassment, lack of physician awareness and an unclear
referral system.
Scope
- Review of the disease definition, classification and key patient
segmentation for FSD
- Assessment of the current unmet needs in the treatment of FSD
- Exploration of the screening, presentation and referral patterns within
the FSD population in the 5EU and US
- Analysis of the prescription and treatment trends among important
subcategories of FSD, such as hypoactive sexual desire disorder (HSDD)
Report Highlights
Testosterone therapies are already widely used among women with HSDD and FSAD.
There is a significant market for a formally approved testosterone product for
women, with 85% of prescribers willing to switch existing testosterone users
onto an approved product.
There is a distinct need for more specialized services in support of those
with sexual functioning problems. There is no clear referral pathway for
primary care physicians and no specialist service for patients to present
directly to. This causes a barrier to presentation, diagnosis and treatment.
The identification and classification of FSD is biased by physician' s
perception. A woman presenting with sexual difficulties could receive a
variety of diagnoses or even no diagnosis at all. There is a need not only for
a more holistic approach to sexual dysfunction, but also for validated and
consistent tools to assess and diagnose patients.
Reasons to Purchase
- Understand key opinion leaders views on topical issues in the FSD market
- View quantified, pictorial treatment pathways of FSD patients in the UK,
US and Spain
- Examine treatment trends for FSD subtypes, HSDD and female sexual arousal
disorder (FSAD)
View Cart
